Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function
Maximilian Brinkhaus, Ruben G J Douwes et al.. The Journal of Immunology 15 December 2020; 205(12): 3456-3467.
Abstract Abs of the IgG isotype mediate effector functions like Ab-dependent cellular cytotoxicity and Ab-dependent cellular phagocytosis by Fc interactions with FcγRs and complement-dependent cytotoxicity upon IgG-Fc binding to C1q. In this study, we describe the crucial role of the highly conserved dual glycines at position 236–237 in the lower hinge region of human IgG, including the lack of one glycine as found in IgG2. We found several permutations in this region that either silence or largely abrogate FcγR binding and downstream FcγR effector functions, as demonstrated by surface plasmon resonance, Ab-dependent cellular phagocytosis, and Ab-dependent cellular cytotoxicity assays. Although the binding regions of FcγRs and C1q on the IgG-Fc largely overlap, IgG1 with a deletion of G236 only silences FcγR-mediated effector functions without affecting C1q-binding or activation. Several mutations resulted in only residual FcγRI binding with differing affinities that are either complement competent or silenced. Interestingly, we also found that IgG2, naturally only binding FcγRIIa, gains binding to FcγRI and FcγRIIIa after insertion of G236, highlighting the crucial importance of G236 in IgG for FcγR interaction. These mutants may become invaluable tools for FcγR-related research as well as for therapeutic purposes in which only complement-mediated functions are required without the involvement of FcγR.
The Latest from Antibody Journal
-
Antibody-Dependent Cellular Cytotoxicity (ADCC) – definition, mechanism & application
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.

-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.

-
Recombinant Antibodies – 7 key insights to rAbs
From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.

-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our body and immune system healthy.
-
Recombinant Antibodies – 7 key insights to rAbs
From the application in medicine and science to recombinant antibody production and the advantages of recombinant Abs in contrast to traditional monoclonal antibodies, this article will teach you all you need to know about recombinant antibodies.
-
Antibody-Dependent Cellular Cytotoxicity (ADCC) – Definition, Mechanism & Application
Antibody-dependent cellular cytotoxicity is a key process of the immune system’s arsenal to ward off cancerous cells and infections. We show you important definitions and the ADCC mechanism and key facts on ADCC antibodies in this post.
-
AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development
STOCKHOLM / 23 April 2026 – Biotech company AAX Biotech, a leading innovator in technologies for antibody-based therapies, today announced a partnership with evitria AG, an expert provider of antibody engineering and expression services, to enable the use of its Opti-mAb® technology in early antibody development workflows. AAX Biotech develops proprietary technologies, including Opti-mAb®, supporting antibody discovery and engineering. Through the partnership, evitria will offer its customers access to Opti-mAb® technology in the design and optimization stages of antibody candidate development across the biotech and pharmaceutical industries. Under the agreement, evitria will provide access to Opti-mAb® under a research license…
-
HEK293 vs. CHO for HTP Expression: Impact on Glycosylation and Folding
Choosing an expression host defines an antibody’s biological signature. While HEK293 is often used for convenience, it introduces significant risks in glycosylation and folding. By aligning HTP screening with CHO-native standards from the start, discovery teams eliminate host-switch leads are truly ready for clinical success.
-
Transient vs. Stable Expression in High-Throughput Antibody Screening: When to Switch
The choice between transient and stable expression defines the pace and precision of an antibody program. While transient systems provide the agility for high-throughput screening, stable cell lines offer the consistency required for clinical manufacturing. Understanding the technical triggers for this switch is essential for optimizing timelines and ensuring manufacturing success.
-
Physical Validation at Scale: How HTP Supports AI-Designed Antibody Discovery
AI accelerates antibody discovery, but physical validation remains essential to bridge the gap between digital design and biological reality. High-Throughput (HTP) platforms enable a ‘lab-in-the-loop’ approach, providing the manufacturing-relevant CHO data needed to refine predictive models and ensure that AI-generated candidates are truly developable from the earliest stage.
-
Fail Fast, Succeed Faster: The Role of Early Developability Assessment
Shifting developability assessment to the early discovery phase represents a strategic opportunity to eliminate high risk candidates before significant investment. By utilizing CHO based expression from the very first screening you ensure that early data is truly predictive of manufacturing success. This proactive approach de risks the journey from the bench to preclinical validation by identifying structural liabilities before they become costly failures.
-
Polyclonal Antibody Production: A Comprehensive Guide
This article will provide a comprehensive guide to polyclonal antibody production (pAb production), outlining the steps involved in the process, discussing the advantages and disadvantages of using polyclonal antibodies, and exploring the alternatives to polyclonal antibody production, including recombinant antibody production.

